Wechselwirkungen · Gilenya
Gilenya 0.25 mg hard capsules Gilenya 0.5 mg hard capsules · Abschnitt 4.5 · PDF-Seite 12
HOS-124779 · Präparat HOS-095937
Fingolimod has been studied in combination with atenolol and diltiazem. When fingolimod was used with atenolol in an interaction study in healthy volunteers, there was an additional 15% reduction of heart rate at fingolimod treatment initiation, an effect not seen with diltiazem. Treatment with Gilenya should not be initiated in patients receiving beta blockers, or other substances which may decrease heart rate, such as class Ia and III antiarrhythmics, calcium channel blockers (such as verapamil or diltiazem), ivabradine, digoxin, anticholinesteratic agents or pilocarpine because of the potential additive effects on heart rate (see sections 4.4 and 4.8). If treatment with Gilenya is considered in such patients, advice from a cardiologist should be sought regarding the switch to non-heart-rate lowering medicinal products or appropriate monitoring for treatment initiation, at least overnight monitoring is recommended, if the heart-rate-lowering medication cannot be stopped.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): atenolol (HOS-087794) diltiazem (HOS-086288) pilocarpine (HOS-124781) digoxin (HOS-086172) calcium (HOS-085615) ivabradine (HOS-109426) verapamil (HOS-090602)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-29T11:20:00Z · SHA-256 14535f3eca03884aa2cdac6745c9ca3473c671171833be03bbc450e2d1533438 · Passage 379a667ee70fbe20a270eba088d97357353b837325926c0292785cd5aff0c2fd · Zeichen 857–1844 im Abschnitt